Anti-Rheumatic Drugs - Cameroon

Cameroon

The Anti-Rheumatic Drugs market in Cameroon is anticipated to achieve a revenue of US$3.25m by the year 2024.
It is expected that this revenue will experience a steady annual growth rate (CAGR 2024-2029) of 0.61%, leading to a market volume of US$3.35m by the year 2029.
In a global context, United States is projected to generate the highest revenue in this market, with an estimated amount of US$34,700.00m in 2024.
Cameroon's demand for anti-rheumatic drugs has surged due to an aging population and increasing prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Cameroon has been steadily growing over the past few years.

Customer preferences: Customers in Cameroon are increasingly looking for affordable and effective anti-rheumatic drugs. As a result, there is a growing demand for generic drugs in the market. Patients are also looking for drugs that have fewer side effects and are easier to administer.

Trends in the market: The Anti-Rheumatic Drugs market in Cameroon has been growing due to the increasing prevalence of rheumatoid arthritis and other rheumatic diseases in the country. The market is also being driven by the increasing availability of affordable generic drugs. In addition, there is a growing trend towards the use of biologic drugs in the treatment of rheumatoid arthritis and other rheumatic diseases.

Local special circumstances: Cameroon is a low-income country with a high burden of rheumatoid arthritis and other rheumatic diseases. The country has a limited healthcare infrastructure, which makes it difficult for patients to access the care they need. As a result, many patients are turning to traditional healers for treatment, which can be dangerous and ineffective.

Underlying macroeconomic factors: Cameroon's economy has been growing steadily over the past few years, which has led to an increase in healthcare spending. The government has also been investing in healthcare infrastructure, which has helped to improve access to care in the country. However, there are still significant challenges in the healthcare system, including a shortage of healthcare workers and limited access to essential medicines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.